Skip to main content
. 2017 Jun 22;7(3):31. doi: 10.3390/metabo7030031

Figure 2.

Figure 2

Significant metabolites identified in the heart 2 weeks after tyrosine kinase inhibitor (or vehicle control) treatment. PCA (principal components analysis) of metabolites identified in sunitinib-treated heart (A). t-test significant metabolites identified in sunitinib-treated heart (B). PCA (principal components analysis) of metabolites identified in erlotinib-treated heart (C). t-test significant metabolites identified in erlotinib-treated heart (D). N = 10/group.